Researchers to develop new diagnostic test for Chagas disease

November 22, 2012 by James Hataway
A UGA faculty member since 1984, Rick Tarleton is the founding director of the Center for Tropical and Emerging Global Diseases.

(Medical Xpress)—Researchers at the University of Georgia will soon begin a study designed to identify new ways of determining treatment efficacy in Chagas disease, a potentially fatal tropical disease that infects approximately 8 million people worldwide and is the leading parasitic killer in the Americas.

There is currently no easy-to-use and reliable test available to assess if Chagas patients receiving treatment are rid of the parasite that causes the disease, . This project will access the performance of commonly prescribed anti-parasitic drugs and hopefully lead to a new, efficient to detect the parasite.

"The major problem in terms of drug treatment for Chagas disease is that it is virtually impossible to determine if the treatment is effective," said Rick Tarleton, Distinguished Research Professor in the Franklin College of Arts of Sciences department of , and member of UGA's Center for Tropical and Emerging Global Diseases. "The detection of T. cruzi is very difficult because of low parasite numbers and the fact that these are primarily in deep tissues such as the heart."

In the first-ever large-scale study, Tarleton will team up with researchers at the Texas Biomedical Research Institute to study treatment of non-human primates that have become infected with the parasite in their outdoor living environment. The animals will be treated with three versus placebo, and a series of blood tests will search for evidence of infection in the blood.

The results from this project have the potential to significantly improve current treatments, but also to open the doors for new, more advanced drugs.

"There are several existing compounds that are available for use in the treatment of Chagas disease, but they are not frequently used because there is not an acceptable test to tell if they actually worked," Tarleton said. "So the drugs go unused and people die."

Major are also hesitant to invest in drug discovery because they have no way of determining whether their drugs work, or if they are better than existing drugs.

Chagas disease is the leading cause of death among young-to-middle-age adults in endemic areas of South America, and many people live years without symptoms while their hearts and digestive systems suffer irreparable damage.

The T. cruzi parasite is most often spread via a subspecies of blood-feeding insects called triatomines. These insects, commonly known as "kissing bugs" because they tend to bite people on the face and lips, feed and defecate on the skin. Triatomine feces containing the parasite are then rubbed into the bite when humans or animals scratch the wound, rub their eyes or touch their mouths.

Once confined almost exclusively to Latin America, has spread throughout the world. In the United States, the Centers for Disease Control and Prevention estimate 300,000 or more people are infected, and it is becoming increasingly common in domesticated dogs and wild animals.

The current project, made possible by support from The Wellcome Trust of the United Kingdom, will begin within months and run until 2015. Texas Biomed will conduct the experimental protocols with the animals and both Texas Biomed and UGA will conduct biomarker analysis.

Tarleton hopes this project will lead to discoveries that save lives and foster the creation of new treatments for this common and underserved disease.

"Identifying a method to accurately and efficiently determine treatment efficacy will increase utilization of existing therapies and will facilitate the discovery of new therapies," he said.

Explore further: FDA approves new test for Chagas disease

Related Stories

FDA approves new test for Chagas disease

November 26, 2011

The Food and Drug Administration has approved Abbott Laboratories' ESA test for Chagas disease, which could be a useful tool in protecting the nation's blood supply from contamination.

UGA animal vaccine may slow deadly spread of Chagas disease

February 16, 2012

Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global ...

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...

Computer model reveals deadly route of Ebola outbreak

November 10, 2015

Using a novel statistical model, a research team led by Columbia University's Mailman School of Public Health mapped the spread of the 2014-2015 Ebola outbreak in Sierra Leone, providing the most detailed picture to date ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.